Exelixis Clinical Site #1

Orlando, Florida 32809

1 studies enrolling now · 2 studies all time

What they study most

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors, Hepatic Impairment, Moderate Hepatic Impairment

Studies at this site

• Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) — Recruiting now
• Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) — Stopped early